Agios Pharmaceuticals (AGIO) Short-term Investments (2012 - 2026)

Agios Pharmaceuticals' Short-term Investments history runs 15 years deep, the most recent figure standing at $623.4 million for Q1 2026.

• Quarterly Short-term Investments fell 23.45% year-over-year to $623.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $623.4 million (down 23.45% YoY) and the FY2025 annual result came in at $765.3 million, down 6.38% from the prior year.
• Short-term Investments was $623.4 million for Q1 2026 at Agios Pharmaceuticals, down from $765.3 million in the prior quarter.
• Across five years, Short-term Investments topped out at $860.2 million in Q3 2025 and bottomed at $479.2 million in Q1 2024.
• A 5-year average of $694.3 million and a median of $688.7 million in 2023 frame the typical range for Short-term Investments.
• Peak annual rise in Short-term Investments reached 88.46% in 2022, while the deepest fall reached 30.1% in 2022.
• Agios Pharmaceuticals' Short-term Investments stood at $643.9 million in 2022, then advanced by 6.97% to $688.7 million in 2023, then grew by 18.69% to $817.5 million in 2024, then fell by 6.38% to $765.3 million in 2025, then decreased by 18.54% to $623.4 million in 2026.
• Business Quant data shows AGIO's Short-term Investments at $623.4 million in Q1 2026, $765.3 million in Q4 2025, and $860.2 million in Q3 2025.